These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7767944)

  • 1. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function.
    Yamamoto N; Tamura T; Maeda M; Ando M; Shinkai T; Eguchi K; Ohe Y; Oshita F; Shiraishi J; Katsumata N
    Cancer Chemother Pharmacol; 1995; 36(2):102-6. PubMed ID: 7767944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cis-diamminedichloroplatinum penetration into the cerebrospinal fluid of the lateral ventricle, postoperative cavity, and lumbar subarachnoid space with or without pre-intravenous mannitol administration in patients with brain metastasis from lung cancer].
    Nakagawa H; Yamada M; Tamura M; Yoshida M; Shindo M; Nishiyama H; Sakai S
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):317-24. PubMed ID: 24743276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor.
    Nakagawa H; Fujita T; Kubo S; Tokiyoshi K; Yamada M; Kanayama T; Hagiwara Y; Nakanomyo H; Hiraoka M
    Cancer Chemother Pharmacol; 1996; 37(4):317-26. PubMed ID: 8548876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
    Leone R; Fracasso ME; Soresi E; Cimino G; Tedeschi M; Castoldi D; Monzani V; Colombi L; Usari T; Bernareggi A
    Cancer Chemother Pharmacol; 1992; 29(5):385-90. PubMed ID: 1312907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose optimization of gallium chloride, orally administered, in combination with platinum compounds.
    Collery P; Millart H; Kleisbauer JP; Paillotin D; Robinet G; Durand A; Claeyssens S; Legendre JM; Leroy A; Rousseau A
    Anticancer Res; 1994; 14(6A):2299-306. PubMed ID: 7825963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
    Minami H; Horio Y; Sakai S; Saka H; Shimokata K
    Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin pharmacokinetics in elderly patients.
    Bonetti A; Franceschi T; Apostoli P; Cetto GL; Recaldin E; Molino A; Leone R
    Ther Drug Monit; 1994 Oct; 16(5):477-82. PubMed ID: 7846745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: a pharmacokinetic approach.
    Morazzoni F; Canevali C; Zucchetti M; Caroli S; Alimonti A; Petrucci F; Giudice G; Masoni E; Bedini AV
    J Cancer Res Clin Oncol; 1998 Jan; 124(1):37-43. PubMed ID: 9498833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.
    Desoize B; Berthiot G; Manot L; Coninx P; Dumont P
    Eur J Cancer; 1996 Sep; 32A(10):1734-8. PubMed ID: 8983282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
    Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of mitomycin C with emphasis on the influence of aging.
    Miya T; Sasaki Y; Karato A; Saijo N
    Jpn J Cancer Res; 1992 Dec; 83(12):1382-5. PubMed ID: 1336497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
    You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
    Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study on quality of life between weekly and monthly chemotherapy with cisplatin, vindesine and mitomycin C in patients with non-small cell lung cancer].
    Ishihara Y; Ichiwata T; Kuramitsu K; Yoneda S; Yamamoto M; Takizawa T; Ogata T; Uchiyama T; Yoshida K
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1013-20. PubMed ID: 9644316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
    Najjar TA; Saad SY
    Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide].
    Desoize B; Maréchal F; Cattan A
    Ann Biol Clin (Paris); 1993; 51(2):125-8. PubMed ID: 8214810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
    J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods].
    Takahashi A; Takagi M; Hishida H; Saji E; Takagi N; Amano H; Ogura Y
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2944-50. PubMed ID: 3116947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.